Arecor Therapeutics and TRx Biosciences collaboration for oral diabetes treatment
LONDON: Arecor Therapeutics plc and TRx Biosciences Limited have entered into a research collaboration to develop an oral form of glucagon-like peptide-1 (GLP-1) receptor agonist,...
Arecor signs co-development agreement with leading global medical products company
CAMBRIDGE, UK: Arecor Therapeutics plc announced a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”)...
Arecor Therapeutics granted key patents in Europe and China
CAMBRIDGE, UK: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, announced that the European Patent Office has granted...